04 Jan Surgical Castration Linked To Fewer Side Effects Than Androgen Deprivation in Prostate Cancer
MedicalResearch.com Interview with:
Quoc-Dien Trinh MD
Assistant Professor, Harvard Medical School
Brigham and Williams Hospital
Medical Research: What is the background for this study? What are the main findings?
Dr. Trinh: Among elderly Medicare beneficiaries with metastatic prostate cancer, surgical castration is associated with lower risks of any fractures, peripheral arterial disease, and cardiac-related complications compared to medical castration using GnRH agonists.
Medical Research: What recommendations do you have for future research as a result of this study?
Dr. Trinh: I find it disconcerting that a perfectly reasonable, cost-effective surgical treatment with potentially less adverse effects and compliance issues than its pharmacologic equivalent has disappeared from medical practice for non-scientific reasons.
Maxine Sun, Toni K. Choueiri, Ole-Petter R. Hamnvik, Mark A. Preston, Guillermo De Velasco, Wei Jiang, Stacy Loeb, Paul L. Nguyen, Quoc-Dien Trinh. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy.
JAMA Oncology, 2015; 1 DOI:10.1001/jamaoncol.2015.4917
Quoc-Dien Trinh MD (2016). Surgical Castration Linked To Fewer Side Effects Than Androgen Deprivation in Prostate Cancer